Wall Street analysts predict that Allena Pharmaceuticals Inc (NASDAQ:ALNA) will post earnings of ($0.51) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Allena Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.39). Allena Pharmaceuticals posted earnings of ($0.48) per share during the same quarter last year, which suggests a negative year over year growth rate of 6.3%. The business is expected to report its next quarterly earnings results on Tuesday, March 26th.

Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Allena Pharmaceuticals.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its earnings results on Wednesday, November 7th. The company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.01.

ALNA has been the subject of several analyst reports. Robert W. Baird initiated coverage on Allena Pharmaceuticals in a research report on Friday, January 18th. They issued an “outperform” rating and a $20.00 target price for the company. B. Riley initiated coverage on Allena Pharmaceuticals in a research report on Sunday, December 30th. They issued a “buy” rating and a $22.00 target price for the company. Jefferies Financial Group initiated coverage on Allena Pharmaceuticals in a research report on Thursday, November 8th. They issued a “buy” rating and a $22.00 target price for the company. Zacks Investment Research upgraded Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 15th. Finally, Wedbush reiterated a “buy” rating and issued a $38.00 price target on shares of Allena Pharmaceuticals in a research note on Tuesday, October 23rd. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $27.63.

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers acquired a new position in shares of Allena Pharmaceuticals in the second quarter worth about $133,000. Citadel Advisors LLC acquired a new position in shares of Allena Pharmaceuticals in the third quarter worth about $116,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Allena Pharmaceuticals in the second quarter worth about $282,000. Bank of New York Mellon Corp lifted its stake in shares of Allena Pharmaceuticals by 205.8% in the second quarter. Bank of New York Mellon Corp now owns 31,137 shares of the company’s stock worth $406,000 after acquiring an additional 20,954 shares in the last quarter. Finally, Alps Advisors Inc. lifted its stake in shares of Allena Pharmaceuticals by 22.3% in the third quarter. Alps Advisors Inc. now owns 36,722 shares of the company’s stock worth $394,000 after acquiring an additional 6,686 shares in the last quarter. Institutional investors and hedge funds own 84.40% of the company’s stock.

Shares of NASDAQ ALNA traded down $0.07 on Tuesday, hitting $7.53. The company had a trading volume of 27,988 shares, compared to its average volume of 34,878. Allena Pharmaceuticals has a 12-month low of $4.80 and a 12-month high of $17.56. The company has a debt-to-equity ratio of 0.17, a current ratio of 14.75 and a quick ratio of 14.75. The company has a market capitalization of $156.32 million, a price-to-earnings ratio of -1.57 and a beta of 1.31.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Featured Article: Should you buy a closed-end mutual fund?

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.